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The varicella zoster virus (VZV) immediate early 62 protein (IE62) activates most if not all identiﬁed
promoters of VZV genes and also some minimum model promoters that contain only a TATA box
element. Analysis of the DNA elements that function in IE62 activation of the VZV ORF3 promoter
revealed that the 100 nucleotides before the translation start site of the ORF3 gene contains the
promoter elements. This promoter lacks any functional TATA box element. Cellular transcription factors
Sp1, Sp3 and YY1 bind to the promoter, and mutation of their binding sites inhibited ORF3 gene
expression. VZV regulatory proteins, IE63 and ORF29, ORF61 and ORF10 proteins inhibited IE62-
mediated activation of this promoter. Mutation of the Sp1/Sp3 binding site in the VZV genome did not
alter VZV replication kinetics. This work suggests that Sp family proteins contribute to the activation of
VZV promoters by IE62 in the absence of functional TATA box.
& 2013 Elsevier Inc. All rights reserved.Introduction
Varicella-zoster virus (VZV) is a human alphaherpesvirus that
belongs to the family Herpesviridae. It is the causative agent of
two diseases, varicella (chickenpox) and herpes zoster (shingles).
The VZV genome is a linear double-stranded DNA molecule of
125 kb and encodes at least 71 genes which are identiﬁed
numerically according to the location of their open reading
frames (ORF) relative to the 50 end of the VZV genome (Cohen
et al., 2007). Upon its entry into the infected cell nucleus, the VZV
genome is transcribed by the host cell RNA polymerase II (RNA
Pol II) and the general transcription apparatus of the cell. By
analogy with herpes simplex virus-1 (HSV-1), the VZV ORFs are
presumed to be expressed as three distinct kinetic classes during
viral infection: immediate early (IE), early and late. All of the IE
gene products appear to be transcriptional regulatory proteins.
Expression of these genes permits transcription of the early genes
that are involved in DNA replication and nucleotide metabolism
and the late genes encoding structural proteins, such as the capsid
proteins and glycoproteins, which are required for assembly of
virions (Cohen et al., 2007).ll rights reserved.
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mediated primarily through functions of the IE62 protein acting
in conjunction with viral and cellular factors. Although several
other proteins encoded by VZV, including the IE4, IE63, ORF10,
and ORF61 proteins have been shown to be capable of transacti-
vating and/or transrepressing speciﬁc viral promoters, (Baudoux
et al., 2000; Defechereux et al., 1997; Moriuchi et al., 1992, 1993a,
1994, 1995; Sato et al., 2003 and Spengler et al., 2000; Wang et al.,
2009;), IE62 is considered to be the primary viral transactivator
driving expression of genes from all three putative kinetic classes
(Kinchington et al., 2000).
To date, only a few VZV promoters have been analyzed in
enough detail to determine their functional elements. However,
these analyses as well as predictions of the positions of putative
promoters within the VZV genome indicate that they are rela-
tively typical RNA Pol II promoters with TATA-like elements and
binding sites for ubiquitous cellular transcription factors
upstream of the TATA elements (Smale and Kadonaga, 2003).
No promoters showing dependence on the presence of an initiator
element (INR) at or just downstream of the start site of transcrip-
tion are known. All of the VZV promoters studied thus far have
been shown to depend on either canonical or non-canonical TATA
elements for activation by IE62 (Peng et al., 2003; Ruyechan et al.,
2003 and Yang et al., 2004) except for the VZV ORF10 promoter as
shown by Che et al. (2007). The ORF10 promoter required the
presence of a USF site and the mutation of this cis-element
inhibited the IE62-mediated transactivation of this promoter.
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promoters have been analyzed at a functional level rather than
that VZV lacks these possible gene regulatory mechanisms.
The biology of VZV infection indicates that control of expression
of the viral genes is essential to the ability of the virus to replicate
productively in cell types that it targets during primary infection,
which include skin and T cells, and to establish and preserve
latency in neurons (Cohen et al., 2007). However, the molecular
mechanisms by which VZV gene expression is regulated are not
well understood. Functional analysis of additional VZV promoters
representing all three putative kinetic classes of VZV genes and
exhibiting differential regulation of viral gene expression is needed
to provide more information about this fundamental process.
Based on this consideration, the work presented here examines
aspects of the regulation of the ORF3 promoter, which results in
expression of ORF3 protein, a late gene product.
VZV ORF3 encodes a predicted 179 amino acid protein with no
known function. ORF3 protein was dispensable for VZV replication
in melanoma cells and skin organ culture in vitro as well as in
human T cells in thymus/liver xenografts in SCID-hu mice infected
in vivo (Zhang et al., 2007, 2010). UL55, the HSV homologue of
ORF3, has been shown to be dispensable for viral replication and
for establishment of latency (Nash and Spivack, 1994).
In the work presented here, we analyzed the ORF3 promoter to
better understand the molecular mechanism of its activation by
IE62. The results demonstrated that ORF3 promoter lacks any
functional TATA box and requires the cellular transcription factors
Sp1, Sp3 and YY1 for its activation. However, the ORF3 promoter
was down regulated by the presence of a suppressor cis-acting
element located in the nucleotide segment from 100 to 120 before
the ORF3 gene translation start site. VZV ORF10, ORF29, ORF61 and
IE63 proteins had inhibitory effects on IE62-mediated transactiva-
tion of the ORF3 promoter. Mutating the Sp1/Sp3 site in the ORF3
promoter in the context of the VZV genome had no effect on viral
replication in MeWo cells. This work suggests that an IE62 and
Sp1/Sp3 mechanism is an alternative to VZV promoter activation
by IE62 through interaction with a TATA-binding protein (TBP).Materials and methods
Cells and viruses
MeWo cells, a human melanoma cell line were grown in Eagle’s
minimal essential medium supplemented with 10% fetal bovine
serum (Spengler et al., 2000). VZV strains MSP and pOka were
propagated in MeWo cell monolayers as described by Lynch et al.
(2002) and Peng et al. (2003).
Nuclear and whole cell lysate preparation and immunoblot analysis
Nuclear extracts of VZV infected MeWo cells were prepared as
previously described (Lynch et al., 2002). MeWo cells were
incubated in buffer A (10 mM HEPES, pH 7.9, 1.5 mM MgCl2,
10 mM KCl, 0.5 mM dithiothreitol) at 4 1C on ice for 15 min to lyse
the cells and release the cytoplasmic fraction. After centrifuga-
tion, the crude nuclear pellet was incubated on ice in buffer C
(20 mM HEPES, pH 7.9, 25% (v/v) glycerol, 0.42 M NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl ﬂuoride,
0.5 mM dithiothreitol). After centrifugation the nuclear extract
was dialyzed against buffer D (20 mM HEPES, pH 7.9, 20% (v/v)
glycerol, 0.1 M KCl, 0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl
ﬂuoride, 0.5 mM dithiothreitol).
Whole cell lysates of VZV infected and pCMV-ORF3 transfected
MeWo cells were prepared in lysis buffer (50 mM Tris–HCl, pH
7.5, 0.15 M NaCl, 1 mM EDTA, 0.1% Triton X-100 and proteaseinhibitor cocktail (Roche, Mannheim, GE) added per the manu-
facturer’s instructions) and analyzed for ORF3 protein by immu-
noblot (10% SDS-PAGE) using a rabbit polyclonal antiserum
against a GST fusion full length ORF3 protein (peng et al., 2003;
and Yang et al., 2006) and IE63 protein using rabbit polyclonal
antibody against full length IE63 protein (Zuranski et al., 2005).
Rabbit polyclonal antibody against b-tubulin was obtained from
Santa Cruz Biotechnology (Santa Cruz, CA.) and mouse mono-
clonal antibody against a-tubulin was obtained from Sigma-
Aldrich. Quantiﬁcation of the relative amounts of ORF3, IE63 a-
tubulin and b-tubulin was done using a BioRad GS700 Imaging
Densitometer (BioRad Hercules, CA). Statistical signiﬁcance was
determined by one-way ANOVA analysis of variance followed by
Tukey’s post hoc test.
Plasmids
A set of luciferase reporter plasmids containing the ORF3
promoter ﬂanked by ﬁreﬂy luciferase was constructed using the
pGL2 basic vector (Promega, Madison, WI). The 336 bp intergenic
region between ORF3 and ORF4 was ampliﬁed by PCR using these
two primers containing a HindIII restriction site at the 50 end and
a XhoI restriction site at the 30 end, respectively; the primer
sequences were 50-ATCAAGCTT TAATTAAACGTTCGGTACACGTCT-
30 and 50-ATCCTCGAGAAATAAAAAATACCTT TTTCATGC-30. The
PCR product was digested and inserted into the pGL2 basic vector
multiple cloning sites between the HindIII and XhoI restriction
sites. The ORF3 promoter truncation that contained the 120
nucleotides from the translation start codon of ORF3 gene was
cloned by ampliﬁcation of the ﬁrst 120 bp by PCR using the ﬁrst
primer as above; the second primer was: 50-ATCCTCGAGTTTT-
TAAGGCGACGTTG GGGATAT-30. This PCR product was inserted
into the basic pGL2 plasmid. The other ORF3 promoter trunca-
tions containing 87, 94 and 100 nucleotides from the translation
start codon were constructed from the 120 nucleotides truncation
construct using the QuikChange Site-Directed Mutagenesis Kit
(Stratagene, LaJolla, CA).
The plasmids containing mutations of the Sp1/Sp3 and YY1
sites and TATA box within the ORF3 promoter were generated
from the wild type pGL2-ORF3 plasmid containing the ORF3/ORF4
intergenic region using the QuikChange Site-Directed Mutagen-
esis Kit (Stratagene, LaJolla, CA). The primer sets for these
mutations were: Sp1/Sp3 site: 50-TGGTTTGAAAGCAATGTAAT
CCTTCCCATATATCCCCAACGTCGC-30 and 50-GCGACGTTGGGGATA-
TATGGGAAGGATTACATTGCTTTCAAACCA-30; YY1 site: 50-TGAAAG
CAATGTAATCCCGCCCGTATATCCCCAACGTCGCCTTAA-30 and 50-
TTAAGGCGACGTTGGGGATATACGGGCGGGATTACATTGCTTTCA-30;
TATA box1: 50-AGTACCGGAATGCCAAGCTTTAGCTAAACGTTCGG-
TACACGTCTG-30 and 50-CAGACGTGTACCGAACGTTTAGCTAAAG
CTTGGCATTCCGGTACT-30; TATA box2: 50- TGAAAGCAATG-
TAATCCCGCCCATATCCCCCCAACGTCGCCTTAA-30 and 50- TTAAG
GCGACGTTGGGGGGATATGGGCGGGATTACATTGCTTTCA-30.The
mutated nucleotides are indicated in bold. All primers were
synthesized by IDT (Coralville, IA). The mutations were veriﬁed
by sequencing at the Roswell Park Cancer Institute sequencing
facility, Buffalo NY.
The pCMV62 plasmid expressing ORF62 under the control of the
cytomegalovirus immediate-early (IE) promoter and the pCMV-
ORF63 and pCMV-ORF29 constructs have been described pre-
viously (Perera et al., 1992a, 1993; Stevenson et al., 1996 and
Zuranski et al., 2005). The pCMV-ORF10, pCMV-ORF61 and pCMV-
ORF4 constructs were kindly provided by P. R. Kinchington (Uni-
versity of Pittsburgh, Pittsburgh, PA).
The pCMV-ORF3 was constructed using pcDNA empty vector
(Invitrogen, Carlsbad, CA). The 540 bp of ORF3 gene was ampliﬁed
by PCR using these two primers containing a HindIII restriction
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respectively; the primer sequences were 50-ATCAAGCTTATGGA-
TACAAC GGGAGCTTCCGAA-30 and 50-ATCCTCGAGTCATAGTCCG
CCGACAGCCGCTCG-30 The PCR product was digested and inserted
into the pcDNA basic vector multiple cloning sites between the
HindIII and XhoI restriction sites.
Reporter gene assays
Luciferase reporter gene assay experiments were performed in
MeWo cells as previously described (Yang et al., 2004). 2105
MeWo cells were seeded in each well of 12-well plates 24 h
before transfection. Cells were transfected with one microgram of
each reporter vector (pGL2-ORF3) using Lipofectamine reagent
(Invitrogen, Carlsbad, CA), along with 5 ng of pEF1a-RL plasmid
(Promega, Madison, WI) as a control for transfection efﬁciency.
The cells were superinfected with VZV MSP 24 h post transfection
(0.4 infected cells per 1 uninfected cell).
In the experiments done in the presence of IE62, the reporter
plasmids were co-transfected along with 5 ng of pCMV-ORF62.
Cells were transfected with IE63, IE4, ORF10, ORF29 and ORF61
plasmids (0.5 mg) separately or with pCMV-ORF62. Dual luciferase
activities were normalized to the Renilla luciferase activities.
pcDNA was transfected along with the pCMV62 plasmid to
equalize the amounts of both total DNA and the promoter
construct in each set of transfections.
The cells were lysed 48 h post transfection or super-infection
in 250 ml of lysis buffer (50 mM HEPES, pH 7.4, 250 mM NaCl, 1%
NP-40, 1 mM EDTA). Control experiments without transfection of
pCMV-ORF62 or VZV infection were done for each plasmid to
determine basal expression levels. Dual-luciferase assays were
performed according to the manufacturer’s instruction. Transfec-
tion experiments were repeated at least three times.
EMSA and supershift analyses
36 bp oligonucleotide probes (IDT, Coralville, IA) containing
wild type and mutant Sp1/Sp3 and YY1 binding sites were used in
electrophoretic mobility shift assays (EMSAs). Probes were end
labeled with ATP [a-32P] using T4 kinase (Invitrogen, Carlsbad,
CA). One hundred femtomoles of the 36 bp labeled probes con-
taining either the wild type or the mutant sequences were
incubated with 15 mg of VZV infected MeWo cell nuclear extract
in a 10 ml reaction mixture in binding buffer (40 mM HEPES,
pH 7.9, 100 mM NaCl, 10 mM MgCl2, 200 mg/ml bovine serum
albumin (BSA), 12% glycerol, 0.05% NP-40, 1 mM dithiothreitol,
and 3 mg poly (dI.dC)). The samples were analyzed by electro-
phoresis on a 5% polyacrylamide (37.5:1 acrylamide/bisacryla-
mide) gel followed by autoradiography. In competition assays, the
ratio of cold probe to labeled probe was 100:1.
In the supershift assays, anti-Sp2, Sp3 and Sp4 antibodies
obtained from Santa Cruz Biologicals (Santa Cruz, CA) or anti-Sp1
antibodies (Upstate, Temecula, CA) and rabbit polyclonal YY1
antiserum, generously supplied by Dr. Te-Chung Lee (University
of Buffalo) were added in 4 mg (Sp family) or 2 ml (YY1) aliquots to
reaction mixtures containing infected cell nuclear extracts and
the 36 bp probe containing the Sp1/Sp3 and YY1 binding sites.
The samples were then analyzed by electrophoresis on a 5%
polyacrylamide (37.5:1 acrylamide/bisacrylamide) gel followed
by autoradiography.
Magnetic bead recruitment assays
Magnetic bead recruitment assays were performed essentially as
described by Lynch et al. (2002). A 100-bp biotinylated DNA fragment
containing the minimal ORF3 promoter elements was purchasedfrom IDT (Coralville, IA). 20 pmol of biotinylated DNA was added to
100 ml of M-280 streptavidin-coated magnetic beads (Dynal, Lake
Success, NY). The mixture was incubated for 15min at room
temperature. The beads were collected using a magnetic particle
concentrator (Dynal), washed twice with 1B&W buffer (10 mM
Tris–HCl, pH 7.5, 1 mM EDTA, and 1M NaCl), and twice with TEN
buffer (10 mM Tris–HCl, pH 7.5, 1 mM EDTA, and 0.1 M NaCl) and
incubated with 500 mg of VZV-infected MeWo nuclear extract for 1 h
at 4 1C in the presence of 3 mg poly (dI.dC). After washing three times
with TEN buffer, the beads were boiled in 2X SDS-PAGE loading buffer
for 10min and analyzed by 10% SDS-PAGE and immunoblot.
Mutation of the ORF3 promoter Sp1/Sp3 site in pOka VZV
Recombinant viruses were generated using overlapping cos-
mids derived from parental Oka (pOka) designated Fsp73 (pOka
nucleotides [nt] 1 to 33128), Spe14 (pOka nt 21795 to 61868),
Pme2 (pOka nt 53755 to 96035), and Spe23 (pOka nt 94055 to
125124) (Niizuma et al., 2003). The ORF3 promoter is located
within the sequence of the cosmid Fsp73. An 11.5 Kb XhoI/SacI
fragment from Fsp73 cosmid was cloned into pLitmus28 to
generate pLitmus XhoI/SacI. Four primers were designed to
amplify the 11.5 kb fragment in two PCR products and ligate
them together with the pLitmus 28 in three PCR product ligation
reaction. The primers sequences for the ﬁrst PCR product: 50-
CCTCTGACTTGAGCGTCGATTTTTG-30, and 50-ATTGCTTTCAAAC-
CAATATCTTTG C-30, and the primers sequence to amplify the
second PCR product which contain the Sp1/Sp3 site mutation in
the ORF3 promoter: 50-GTAATCCTTCCCATATATCCCCAA C-30 and
50-GCCATCTTCCACGGGTCATGC-30. Mutated nucleotides are indi-
cated in bold. The ﬁrst nucleotide of the second primer amplifying
the ﬁrst PCR product (A) is adjacent to the ﬁrst nucleotide of the
ﬁrst primer amplifying the second PCR product (G). PCR reactions
were done with Accuprimer Pfx polymerase (Invitrogen). The left
PCR product was digested with XhoI and the right PCR product
was digested with NcoI. The digested PCR products were cloned
into XhoI/NcoI digested pLitmus XhoI/SacI plasmid to generate
pLitmus XhoI/SacI ORF3 promoter. Mutations were veriﬁed by
DNA sequencing (Quintara Biosciences, South San Francisco, CA).
The XhoI/SacI fragment from the pLitmus XhoI/SacI ORF3 promo-
ter construct was to introduce the ORF3 promoter mutation into
the Fsp73 cosmid.
Recombinant viruses were made by transfection of melanoma
cells with either the wild type or the mutated Fsp73 cosmid and
the other three intact cosmids, Spe14, Spe23 and Pme2. To
conﬁrm the Sp1/Sp3 site mutation, genomic DNA was extracted
from virus-infected melanoma cells with DNAzol (Invitrogen,
Carlsbad, CA). A PCR fragment covering the mutated region was
ampliﬁed from the genomic DNA, gel-puriﬁed with a QIAquick gel
extraction kit (Qiagen, Inc., Valencia, CA), and sequenced (Elim
Biopharm, Inc., Hayward, CA).
The replication kinetics of the recombinant viruses was
assessed by an infectious focus assay with immunostaining using
anti-VZV monoclonal antibody (Meridian) to detect plaques
(Chaudhuri et al., 2008 and Moffat et al., 1995). Statistical differ-
ences in growth kinetics were determined by Student’s t test.Results
Mapping of the ORF3 promoter and identiﬁcation of the cis-acting
elements that regulate this promoter
To map the ORF3 promoter structure, luciferase reporter gene
assays were done using constructs that included portions of the
intergenic region between ORF3 and ORF4 genes (Fig. 1A and B).
Fig. 1. The ORF3-ORF4 intergenic region. (A). Schematic diagram shows the structure of the VZV genome and the position of the intergenic region between ORF3 and ORF4
genes includes the ORF3 promoter. UL and US are the unique long and unique short segments of the genome, respectively. TRL and IRL are the terminal and internal repeat
sequences of UL. TRS and IRS are the terminal and internal repeat sequence of the US. The numbers below the ORF3-ORF4 intergenic region represent the nucleotide
positions of the beginning and end of the region in the VZV MSP strain. (B) Nucleotide sequence of the ORF3-ORF4 intergenic region. The arrows indicate the truncations
used in the reporter gene assays for mapping the intergenic region for the presence of ORF3 promoter elements. TBP sites are underlined, Sp1/Sp3 site is boxed and YY1 site
is in italics.
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translation start site and the stop codon of the ORF4 gene.
Expression of the ORF3 reporter gene was assessed in the context
of VZV super-infection and pCMV-62 transfection, using the
pGL2-ORF3 plasmid that expressed ﬁreﬂy luciferase under the
control of the ORF3 promoter or ORF3 promoter truncations. The
activity of the promoter constructs in the presence of VZV
infection or pCMV-62 was determined as induction (n-fold) of
the luciferase activity compared to the basal activity observed
without infection or pCMV-62 transfection, respectively.
The analysis of the intergenic region showed that the 100
nucleotides immediately adjacent to the ORF3 translation start
site displayed the maximum luciferase activity in context of both
pCMV-62 transfection and VZV super-infection (Fig. 2A and B).
These results suggested that this 100 bp region contained the
promoter cis-acting elements for ORF3 gene and included the
essential elements required for ORF3 promoter activation. ORF3
promoter activation was low in absence of IE62 or VZV super-
infection. The ﬁrst two constructs containing 87 and 94 nucleo-
tides, respectively, from the ORF3 gene translation start site
showed particularly low expression levels (10–15%) compared
to the maximum activity observed with the 100 bp construct.
In contrast, the two constructs which included the nucleotides
between 100 and 120 had 2-fold less activity than the 100 bp
construct, suggesting that this 20 bp segment contained repres-
sive cis-elements regulating the ORF3 promoter activity as
mediated either by IE62 alone or VZV infection. Bioinformatics
analysis of these 20 nucleotides for putative cellular transcription
factors binding sites suggested binding sites for the Sp family and
NFkB proteins but experimental analysis did not show binding of
these factors to 30 bp oligonucleotides containing this sequence
(data not shown).The 100 bp segment immediately upstream of the ORF3 gene
translation start site was then analyzed for the presence of
cellular transcription factor binding sites using the AliBaba2.1
and Patch programs (http://www.gene-regulation.com/pub/pro
grams.html; Biobase). A GC-rich sequence was identiﬁed from
88 to 94 bp before the ORF3 gene translation start site. This GC-
rich sequence contained predicted binding sites for Sp family
cellular transcription factors. A potential binding site (50-CCCA-
TATAT-30) for the cellular transcription factor YY1 was also
identiﬁed that partially overlapped the GC-rich sequence as well
as two postulated TATA box sites. The ﬁrst one was immediately
adjacent to the translation start codon of the ORF3 gene and the
second partially overlapped the predicted YY1 binding site. Based
on the bioinformatics results and the reporter gene assays,
experiments were done using EMSA, supershift, and mutational
analyses in order to determine whether the GC-rich sequence and
the YY1 site were bona ﬁde binding targets for the speciﬁc cellular
transcription factors.
Sp1/Sp3 bind to the GC-rich sequence and YY1 binds to the predicted
YY1 binding site
In the ﬁrst series of experiments, EMSA and supershift assays
were performed using 36 bp duplex oligonucleotides containing
both the GC-rich sequence and the predicted YY1 binding site in
the presence of a nuclear extract from VZV infected MeWo cells.
Numerous complexes were formed using this 36 bp oligonucleo-
tide, including two major slowly migrating complexes (Fig. 3B).
Antibody supershift assays were then done to assess the binding
of the Sp family members and the YY1 cellular transcription
factors to these sequences. The anti-Sp1 antibody supershifted
part of the upper major complex and the anti-Sp3 antibody
Fig. 3. EMSA and supershift assays using 36 bp oligonucleotides containing the wild-type GC rich sequence and the YY1 site of the ORF3 promoter. (A) Sequence of the
36 bp oligonucleotide. The GC rich sequence is underlined and the YY1 site is boxed. Supershift assays were done in the presence of VZV-infected cell nuclear extracts.
(B) Polyclonal antibodies against Sp1, Sp2, Sp3 and Sp4 were used in the supershifts as indicated. (C) Polyclonal antibody against YY1 was used in the supershifts as
indicated. The YY1 supershift assay gel was exposed in two stages with the upper part being developed for a shorter time in order to better visualize the two separate
complexes of the newly formed supershifted YY1 complex and the original Sp1 containing complex. Lanes: FO, free oligonucleotide; I, VZV-infected nuclear extract. The
positions of the original major complexes are indicated by arrows and the positions of the supershifted bands are indicated by asterisks.
Fig. 2. Mapping the cis-acting elements that inﬂuence ORF3 promoter activity. Reporter gene assays were done to determine the effects of truncation constructs containing
segments of the ORF3-ORF-4 intergenic region on ORF3 promoter activation. Experiments were done in triplicate with (A) pCMV-ORF62 transfection and (B) VZV super-
infection. The promoter activities resulting from the presence of pCMV-ORF62 or VZV super-infection are reported as induction (n-fold) of luciferase activity over basal
(without ORF62 transfection or VZV super-infection). Statistical signiﬁcance was determined by a one-way ANOVA analysis of variance followed by Tukey’s post hoc test.
Error bars indicate standard error.
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anti-YY1 antibody also completely supershifted one of the minor
complexes formed using these 36 bp oligonucleotides (Fig. 3C).
In contrast, no supershifts or loss of complexes were observed in
the presence of anti-Sp2 or anti-Sp4 antibodies.
Next, EMSAs were performed using oligonucleotides containing
mutations in the consensus Sp1 binding site located in the GC-rich
sequence and in the YY1 binding site. Site-speciﬁc mutagenesiswas used to substitute CG residues with TT in the GC-rich sequence
and the ﬁrst A following the GC-rich sequence was mutated to G.
These mutations were predicted to abolish binding of Sp1 and Sp3
and YY1, respectively. As shown in Fig. 4B and C, both mutations
ablated the formation of the YY1 complex even though altering the
GC-rich sequence was not predicted to affect YY1 binding to the
sequence. Quantitative analyses showed that the substitutions in
the GC-rich sequence inhibited the formation of the Sp1 and Sp3
Fig. 4. EMSA assays using wild type, Sp1/Sp3 mutant and YY1 mutant duplex oligonucleotides. (A) Sequences of the oligonucleotides containing the wild type and mutant
oligonucleotides. The GC rich sequence is underlined and the YY1 site is boxed. Typical EMSA results showed binding to wild type probe as well as the mutant probe in
experiments using (B) Sp1/Sp3 mutant probe or (C) the YY1 mutant probe. Lanes: FO, free oligonucleotide; I, VZV-infected nuclear extract. The positions of the original
complexes are indicated by arrows.
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YY1 binding site inhibited the formation of these Sp1 and Sp3
complexes by 20%.
To test the speciﬁcity of the formation of these complexes,
competition EMSA experiments were done using the unlabeled
36-bp containing the GC-rich sequence and the predicted YY1
binding site as the speciﬁc competitor and a 30-bp oligonucleo-
tide containing the origin binding protein (OBP) box A sequence
as the nonspeciﬁc competitor (Khalil et al., 2008). As shown in
Fig. 5B, the cold speciﬁc competitor efﬁciently competed away the
formation of these complexes, while the presence of the non-
speciﬁc competitor had no effect on the pattern of the shifted
bands. These experiments indicated that cellular transcription
factors Sp1, Sp3 and YY1 bind speciﬁcally to the ORF3 promoter
element.
Next, magnetic bead recruitment assays were done to identify
the viral and cellular proteins that were involved in gene
transcription and bound to the 100 bp oligonucleotides contain-
ing the ORF3 promoter. As shown in Fig. 5C, the cellular tran-
scription factors Sp1, Sp3 and YY1 and IE62 were able to bind to
the ORF3 minimal promoter sequence. In contrast, the TBP
protein did not bind to this sequence under these experimental
conditions.
Sp1/Sp3 and YY1 site mutations inhibited ORF3 promoter activity
In order to test the effects of the binding of Sp1, Sp3 and YY1 to
these sequences on ORF3 promoter activation, the mutations that
were determined to inhibit binding were introduced in the full
length reporter construct containing the complete intergenic
region between ORF3 and ORF4 genes. Reporter gene assays were
done in the context of VZV super-infection and with pCMV-62
transfection. Luciferase activities obtained from each reporterplasmid in the absence of VZV super-infection and ORF62 trans-
fection represent the basal levels from this plasmid and were
normalized to 1. Reporter gene activities in the presence of VZV
super-infection and ORF62 transfection were reported as induc-
tion (n-fold) of luciferase activities in reference to the basal
activity without VZV super-infection or ORF62 transfection. Both
the Sp1/Sp3 and the YY1 site mutations inhibited ORF3 promoter
activation by about 80% in the experiment done using pCMV-
ORF62 transfection and 85–90% in VZV super-infection experi-
ments (Fig. 6A and B). In contrast, these mutations did not
inﬂuence ORF3 promoter activity signiﬁcantly in the absence of
IE62 or VZV superinfection. These results suggested the involve-
ment of these cellular transcription factors in the activation of the
ORF3 promoter mediated by IE62 or by VZV super-infection. In
contrast, the mutations of the two putative TATA boxes had no
effect on ORF3 promoter activation in the context of either VZV
infection or pCMV-ORF62 transfection (Fig. 6A and B).Transactivation of the ORF3 promoter by VZV regulatory proteins
In these experiments, the pGL2-ORF3 reporter that included
the complete 336 bp intergenic region between ORF3 and ORF4
genes was used in reporter gene assays. The plasmids encoding
the VZV regulatory proteins IE62, IE63, ORF61, ORF10, IE4 and
ORF29 were co-transfected individually into MeWo cells with the
reporter pGL2-ORF3 plasmid. The transactivation results were
presented as n-fold induction compared to the luciferase activity
with the empty vector, which was normalized to 1. As expected,
IE62 had potent transactivation effects on the ORF3 promoter
(about 50-fold activation). In contrast none of other VZV regula-
tory proteins, IE4, ORF61, and IE63, ORF10 and ORF29, transacti-
vated the ORF3 promoter (Fig. 7).
Fig. 5. EMSA and competition assays using a 36-bp oligonucleotide containing the wild type Sp1/Sp3 and YY1 sites in the presence of VZV-infected cell nuclear extracts.
(A) Sequences of the two oligonucleotides used in the assays. The Box A oligo was used as the nonspeciﬁc competitor. (B) Competition assays using a 100-fold excess of
cold wild type speciﬁc competitor and nonspeciﬁc competitor. The positions of the Sp1, Sp3 and YY1 complexes are indicated by arrows. (C) Magnetic-bead recruitment
assays showing the binding of IE62, Sp1, Sp3 and YY1 to the 100 bp biotinylated duplex oligonucleotides containing the ORF3 promoter cis-acting elements. a-TBP was
used as a negative control.
Fig. 6. The effect of mutations of the Sp1/Sp3 and YY1 sites and putative TATA boxes in the ORF3 promoter on ORF3 gene expression. Results of triplicate assays assessing
the effects of the presence of the Sp1/Sp3 and YY1 site mutations on the expression levels of the ﬁreﬂy luciferase reporter gene present at the position of the ORF3 gene in
the context of (A) pCMV-ORF62 transfection and (B) VZV super-infection. The promoter activities resulting from the presence of transfected ORF62 or VZV super-infection
are reported as induction (n-fold) of luciferase activity over basal (without ORF62 transfection or VZV super-infection, respectively). Statistical signiﬁcance was determined
by a one-way ANOVA analysis of variance followed by Tukey’s post hoc test. Error bars indicate standard error.
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vators on IE62-mediated activation of the ORF3 promoter, IE62
was co-expressed with IE4, ORF61, IE63, ORF10 or ORF29. IE4 had
no signiﬁcant inﬂuence on IE62-mediated transactivation of theORF3 promoter. However, the other VZV regulatory proteins
inhibited IE62-mediated activation with inhibition of 2-fold
by ORF29 and ORF10 proteins and 3-fold by IE63 (Fig. 7).
Of interest, ORF61 protein showed maximum inhibition of the
M.I. Khalil et al. / Virology 440 (2013) 171–181178IE62-mediated activation of the ORF3 promoter of 10-fold.
These results suggested a possible mechanism for downmodula-
tion of IE62-mediated transactivation of late gene expression
mediated by other VZV regulatory proteins.
Mutating the Sp1/Sp3 site in the ORF3 promoter did not affect VZV
replication in vitro
Introducing the Sp1/Sp3 site mutation into the VZV genome using
the pOka cosmids yielded recombinant virus with the expectedFig. 7. Transactivation of the ORF3 promoter by VZV proteins. MeWo cells were
transfected with the full-length pGL2-ORF3 promoter and plasmids expressing
IE4, ORF10, ORF61, IE62, IE63, ORF29 or IE62 together with IE4, ORF61, ORF10,
ORF29 or IE63. Cells were harvested at 48 h post-transfection, and the dual
luciferase assay was performed. The promoter activities resulting from the
presence of transfected VZV proteins are reported as induction (n-fold) of
luciferase activity over basal (without VZV protein expression). Statistical sig-
niﬁcance was determined by a one-way ANOVA analysis of variance followed by
Tukey’s post hoc test. Error bars indicate standard error.
Fig. 8. The effect of VZV pOka-Sp1/Sp3 site mutation in the ORF3 promoter on VZV repl
in MeWo cells. Cells were inoculated at 103 PFU/ml with wild type and mutant viruses a
Sp1/Sp3 site mutation on ORF3 expression levels in MeWo cells during VZV infection
plasmid. Western blot analyses show the expression levels of ORF3, IE63, a-tubulin an
control in the experiments. The blots were scanned by densitometry to obtain quantitati
analysis of variance followed by Tukey’s post hoc test.sequence change compared to the recombinant generated with
intact pFsp73 cosmid (recombinant wild type virus). When the
growth kinetics of pOka and the ORF3 promoter mutant were
compared in MeWo cells, titers were equivalent over the ﬁrst ﬁve
days post infection with a slight decrease for the ORF3 promoter
mutant at day 6 (Fig. 8A). The expression of ORF3 protein in the
whole cell lysate of MeWo cells transfected with pCMV-ORF3
expressing plasmid showed that the presence of 19 kDa protein
equivalent to the expected molecular weight of ORF3 protein
(179 amino acids). Then we evaluated the inﬂuence of this ORF3
promoter mutation on the expression of the ORF3 protein in infected
MeWo cells. The promoter mutation was associated with a signiﬁ-
cant reduction in ORF3 protein synthesis of about four-fold based on
densitometer analyses done at 36 h post-infection, compared to
pOka (Fig. 8B). Also, the expression level of IE 63 was determined
in the wild type as well the ORF3 mutant viruses. We have found
that equal expression of the IE63 protein in the two viruses.
The expression level of IE63 protein here was used as a control
for the level of infection in the wild type and ORF3 mutant virus
preparations.Discussion
This analysis mapped the ORF3 promoter and identiﬁed cis-
acting elements that affect activation of the ORF3 promoter
activation mediated by IE62, the major VZV trans-activator. This
work shows that ORF3 activation occurs by an alternative
mechanism that is independent of the putative TATA box
site(s) in the ORF3-ORF4 intergenic region. In the case of ORF10
promoter, we suggested that the absence of the TATA element
might be overcome by the recruitment of the TBP to the ORF10
promoter through the physical interaction with IE62 or USF (Peng
et al., 2003 and Yang et al., 2006). However, the binding of TBP to
ORF10 promoter was not assessed whereas these experiments
showed that TBP does not bind to ORF3 promoter.
The VZV genome is transcribed by the host cell RNA polymerase
II (RNA Pol II). RNA polymerase II transcription is initiated through
the assembly of the pre-initiation complex (PIC) consisting of the
general transcription factors (GTFs, TFIID, TFIIA, TFIIB, TFIIF, TFIIE
and TFIIH) (Orphanides et al., 1996). The efﬁciency of the formationication in MeWo cells. (A) Growth kinetics of pOka and pOka-Sp1/Sp3 mutant virus
nd infectious virus yields were determined for 6 days after inoculation. (B) Effect of
and the expression of ORF3 protein in MeWo cells transfected with pCMV-ORF3
d b-tubulin at 36 h post-infection. a-tubulin and b-tubulin were used as a loading
ve data (in triplicate). Statistical signiﬁcance was determined by a one-way ANOVA
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and thus is a common site of both positive and negative transcrip-
tional regulation (Choy and Green, 1993). TFIID is a large protein
complex consisting of the TBP and its associated factors TAFs
(Nakajima et al., 1988). In eukaryotes, TBP is responsible for the
assembly of the transcription initiation machinery at TATA box
containing promoters as a component of the TFIID complex. More-
over, a TFIID complex containing TBP is essential for transcription
even when the eukaryote gene promoter lacks a TATA box (Pugh
and Tjian, 1991). VZV promoters are characterized by the fact that
the TATA-elements required and/or predicted to be positioned
correctly for expression are frequently atypical and therefore less
likely to be bound with high afﬁnity by the TATA-binding protein
(TBP) (Ruyechan et al., 2003). Although some VZV transcripts
are generated using canonical TATA sequences (TATAAA), as in the
case of ORF61, other transcripts arise from non-canonical TATA
sequences like TTTTAA (ORF62), ATAAAA (ORF67), ATTTAAATT
(ORF14) or TATGTAAA (ORF28) (Stevenson et al., 1992; McKee and
Preston, 1991; Ling et al., 1992 and Meier and Straus, 1993).
In the present experiments, we found that the ﬁrst 100
nucleotides before the translation start site of the ORF3 gene
were required for ORF3 expression in a reporter construct. These
100 nucleotides have two putative TATA boxes but mutation of
these sites did not affect ORF3 promoter activation and TBP did
not bind to a 100 bp oligonucleotide sequence containing the
ORF3 promoter cis-elements. These observations indicate that
IE62 utilizes a different mechanism to activate the ORF3 promo-
ter. The cellular transcription factors Sp1, Sp3 and YY1 were
shown to bind to this sequence and mutation of their proposed
binding sites inhibited interaction and also inhibited transactiva-
tion of ORF3 promoter mediated by IE62 or VZV superinfection
signiﬁcantly. These results pointed to a role for Sp1, Sp3 and YY1
interactions with IE62 in absence of any functional TATA box in
achieving recruitment of basal transcription machinery to the
ORF3 promoter, leading to its activation.
Many viral and cellular promoters transcribed using RNA
polymerase II lack any obvious TATA box predicted to bind TFIID.
These cellular and viral genes include those encoding for dihy-
drofolate reductase, c-H-ras, adenine deaminase, TGF-a, thymi-
dylate synthase and SV-40 late gene products and EBV latent
membrane protein1 LMP1 (Dynan et al., 1986; Swick et al., 1989;
Carcamo et al., 1989; Mitchell et al., 1987 and Sadler and Raab-
Traub, 1995). These TATA-less promoters are characterized by the
presence of GC boxes which are the binding site for the Sp family
members of transcription factors and their transcription initiation
is critically dependent on Sp1 (Pugh and Tjian, 1991). On the
other hand, many other TATA-less genes are regulated during cell
growth and their transcription is stimulated during cell prolifera-
tion (Azizkhan et al., 1993). Among these, two TATA-less promo-
ters in the rat for haploid-speciﬁc Oxct2b gene and catalase
required cAMP responsive element (CRE) and CCAAT/enhancer
binding protein-beta, respectively, (Somboonthum et al., 2005
and Taniguchi et al., 2005). In HSV-1, an alphaherpesvirus closely
related to VZV, UL9 and ICP34.5 promoters do not have a
canonical TATA box site (Deb et al., 1993 and Sarisky and
Weber, 1994). However, these promoters may have a non-
canonical TATA box. The ICP34.5 promoter sequence has a
predicted non-canonical TATA-box site that is similar to the TATA
site shown to be functional for the activation of UL38 promoter
(Sarisky and Weber, 1994). The promoter of HSV-1 UL55, the
ORF3 homologue, has not been analyzed.
The physical and functional interaction between IE62 and Sp1
has been demonstrated previously (Narayanan et al., 2007 and Peng
et al., 2003). Analyses of several VZV promoters have identiﬁed
functional GC rich elements that are required for binding of the Sp
family of cellular transcription factors. Some of these sites have thecanonical Sp1 site (50-GGGCGGG-30) identiﬁed in the SV40 early
promoter by Dynan and Tjian (1983). Sp1 regulates the gI and gE
promoters in transient transfection assays and as demonstrated by
mutagenesis in the VZV genome; GC rich elements have been
identiﬁed in IE4 and IE63 promoters (Berarducci et al., 2007; He
et al., 2001; Ito et al., 2003; Kinchington et al., 1994; Rahaus and
Wolff, 1999, 2000). Sp1 sites are also identiﬁed in the ORF61
promoter and disrupting these sites in the VZV genome affected
not only the expression of ORF61 but also virus growth in skin
xenografts in vivo (Wang et al., 2009). In addition, bioinformatics
analysis reveals a high frequency of predicted Sp1 sites within VZV
gene promoters, indicating a minimum of 18 beyond those that
have already been authenticated (Ruyechan et al., 2003).
The role of Sp family members other than Sp1 in VZV infection
is unknown except for the demonstration of Sp3 binding to the
Sp1/Sp3 site in the downstream region of oriS, which supports a
role for this transcription factor in the VZV life cycle (Khalil et al.,
2008). Of interest, the mutation of this Sp1/Sp3 site in the
downstream region of VZV oriS inhibited both origin dependent
DNA replication and ﬂanking gene transcription in transient
transfection assays (Khalil et al., 2012), suggesting a possible role
for Sp3 in replication as well as promoter activation.
YY1 is a 414 amino acid zinc-ﬁnger protein capable of repres-
sion and activation of gene transcription in several viruses,
including adeno-associated virus, human papillomavirus, parvo-
virus B19, HSV-1 and Moloney murine leukemia virus (Lee et al.,
1992, 1998; Pajunk et al., 1997 and Shi et al., 1997). Information
about the role of YY1 in VZV replication and infection is limited.
We established that YY1 binds to the downstream region of VZV
oriS but the mutation of this binding site had no signiﬁcant effect
on either origin-dependent DNA replication or expression of the
ORF62 and ORF63 ﬂanking genes. However, mutation of this YY1
site in a VZV recombinant virus was associated with an increase
in total virus DNA level in MeWo cells and VZV growth in skin
xenografts (Khalil et al., 2008, 2012).
YY1 has been shown to physically interact with Sp1 (Lee et al.,
1993; Seto et al., 1993 and Shi et al., 1997), raising the possibility that
binding could occur between YY1 and Sp1 at their respective sites in
the ORF3 promoter. This binding may be important for the recruit-
ment of YY1 to the ORF3 promoter or at least for stabilizing the
formation of the YY1 complex. This hypothesis were supported by
our ﬁnding that mutation of the Sp1/Sp3 site, which was not expected
to affect YY1 binding to the ORF3 promoter, not only inhibited the
formation of the Sp1/Sp3 containing complexes but also ablated
the formation of the YY1 complex. These results also suggest that the
effect of the Sp1/Sp3 site mutation on ORF3 expression may be due
not only to the inhibition of Sp1 and Sp3 binding to the site but also
to the absence of YY1 binding to its site in the ORF3 promoter.
We found that the ORF3 promoter was trans-activated only by
IE62 and not by IE4, IE63, ORF10, ORF29 or ORF61 proteins. With
the exception of IE4, all of these VZV proteins down-regulated
IE62 mediated transactivation of the ORF3 promoter. ORF29 and
ORF10 proteins inhibited ORF3 promoter transactivation by about
2-fold and IE63 reduced IE62 activation by about 3-fold. ORF61
exhibited the most signiﬁcant effect, inhibiting the response to
IE62 by about 10-fold. This interplay between the VZV regulatory
proteins has been reported in experiments showing that ORF29
and IE63 enhance IE62 activation of the gI promoter in MeWo
cells (Boucaud et al., 1998 and He et al., 2001). IE63 also has been
shown to up-regulate the IE62-mediated transactivation of the
ORF66, ORF61 and gE promoters (Folster et al., 2011; Wang et al.,
2009 and Berarducci et al., 2007). In contrast, ORF61 was
determined to be the major viral trans-repressor of IE62 trans-
activating functions in Vero cells (Nagpal and Ostrove, 1991) even
though ORF61 expressed without IE62 activated the ORF4, ORF61
and ORF62 promoters in Vero cells (Moriuchi et al., 1993b).
Fig. 9. A model for the mechanism by which IE62 mediates the transactivation of
the VZV promoters during VZV infection. (A) In the presence of the TATA box site,
the IE62 is able to dimerize, bind to DNA and has the ability to bind to other
cellular transcription factors like Sp1, Sp3 and the Mediator complex and activate
the initiation of the gene transcription. (B) In the absence of a TATA box site, IE62
can utilize other cellular transcription factors binding to sites like that of the Sp1,
Sp3 and YY1. These binding sites may act as an alternative to compensate for the
absence of the functional TATA box; IE62 binding to DNA and to some of these
cellular factors may recruit the basal cellular transcription machinery and activate
TATA-less promoters like the ORF3 promoter. This model does not exclude the
recruitment of TFIID complex components to the promoter.
M.I. Khalil et al. / Virology 440 (2013) 171–181180These observations showing that the Sp1/Sp3 and YY1 sites are
required for IE62 mediated transactivation of the ORF3 promoter in
the absence of any functional TATA box element suggests an
alternative mechanism by which IE62 can activate VZV promoters.
In this mechanism, the physical interaction between IE62 and
cellular transcription factors Sp1 and USF (and probably other
cellular transcription factors including Sp3 and YY1) may act as a
platform in the presence of IE62 for recruiting the basal transcrip-
tion machinery to the VZV promoters and the formation of a stable
pre-initiation complex (PIC) (Fig. 9). This model does not exclude
the possibility of the presence of TFIID complex components in the
activation of these promoters. This model may help to expand our
understanding of the mechanisms used by IE62 to activate tran-
scription of speciﬁc VZV genes based on the characteristics of their
promoter binding sites for cellular trans-activating factors.Acknowledgments
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